News Theralase Technologies Inc.

Equities

TLT

CA88337V1004

Delayed Toronto S.E. Other stock markets 09:52:32 2024-04-16 am EDT			5-day change	1st Jan Change
0.18 ^CAD	0.00%		+9.09%	+2.86%

Apr. 05	Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent	CI
Mar. 27	Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent	Apr. 05	CI
Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Theralase Technologies Donates Cool Laser Therapy Technology to Aid in R&D of Treatment for Parkinson's Disease	Feb. 12	MT
Theralase Technologies shares update on Phase II Bladder Cancer study	Feb. 08	AQ
Theralase Technologies Closes C$1.2-Million Private Placement of Share Units	Feb. 05	MT
Theralase Technologies Inc. announced that it has received CAD 1.200001 million in funding	Feb. 04	CI
Theralase Technologies Provides Update on Phase II Bladder Cancer Clinical Study	Jan. 15	MT
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study	Jan. 15	CI
Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA	Dec. 04	AQ
Theralase Technologies Raises C$1.17 Million in a Private Placement of Share Units	Nov. 29	MT
Theralase Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Theralase Technologies Inc. announced that it has received CAD 1.17 million in funding	Nov. 28	CI
Theralase Technologies Raising up to C$1.5 Million in a Private Placement of Share Units	Nov. 17	MT
Theralase Technologies Inc. announced that it expects to receive CAD 1.5 million in funding	Nov. 16	CI
Theralase Technologies : Amended LIFE Offering Document	23-10-27	PU
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study	23-10-23	CI
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study	23-10-16	CI
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-09	AQ
Theralase Technologies Inc. Files US Patent for Enhanced Immunotherapy	23-10-05	CI
Theralase®? Technologies Inc. Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer	23-09-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Theralase Technologies Inc.

Equities

TLT

CA88337V1004

Summary

Filters